These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 29355037)

  • 1. Neoadjuvant and adjuvant treatment in high-risk prostate cancer.
    Bandini M; Fossati N; Gandaglia G; Preisser F; Dell'Oglio P; Zaffuto E; Stabile A; Gallina A; Suardi N; Shariat SF; Montorsi F; Karakiewicz PI; Briganti A
    Expert Rev Clin Pharmacol; 2018 Apr; 11(4):425-438. PubMed ID: 29355037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy.
    Jackson WC; Schipper MJ; Johnson SB; Foster C; Li D; Sandler HM; Palapattu GS; Hamstra DA; Feng FY
    Eur Urol; 2016 Jan; 69(1):50-7. PubMed ID: 26004800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological effect of neoadjuvant androgen-deprivation therapy assessed on specimens from radical prostatectomy: a systematic review.
    Antonelli A; Palumbo C; Veccia A; Grisanti S; Triggiani L; Zamboni S; Furlan M; Simeone C; Magrini S; Berruti A
    Minerva Urol Nefrol; 2018 Aug; 70(4):370-379. PubMed ID: 29392925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant versus neoadjuvant androgen deprivation with radiotherapy for prostate cancer: does sequencing matter?
    Weller MA; Kupelian PA; Reddy CA; Stephans KL; Tendulkar RD
    Clin Genitourin Cancer; 2015 Jun; 13(3):e183-9. PubMed ID: 25660127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant Approaches Prior To Radical Prostatectomy.
    Ryan ST; Patel DN; Parsons JK; McKay RR
    Cancer J; 2020; 26(1):2-12. PubMed ID: 31977379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and emerging therapies for localized high-risk prostate cancer.
    Moris L; Devos G; Van den Broeck T; Milonas D; Albersen M; Berghen C; De Meerleer G; Devlies W; Everaerts W; Gevaert T; Van Poppel H; Claessens F; Joniau S
    Expert Rev Anticancer Ther; 2021 Mar; 21(3):267-282. PubMed ID: 33225759
    [No Abstract]   [Full Text] [Related]  

  • 7. Adjuvant and neoadjuvant therapies in high risk localized prostate cancer.
    Giannakopoulos X; Stagikas D; Charalabopoulos A; Sofikitis N; Charalabopoulos K
    J Exp Clin Cancer Res; 2006 Dec; 25(4):469-73. PubMed ID: 17310835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additional therapy for high-risk prostate cancer treated with surgery: what is the evidence?
    Morgan SC; Dearnaley DP
    Expert Rev Anticancer Ther; 2009 Jul; 9(7):939-51. PubMed ID: 19589033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The addition of chemotherapy in the definitive management of high risk prostate cancer.
    Ferris MJ; Liu Y; Ao J; Zhong J; Abugideiri M; Gillespie TW; Carthon BC; Bilen MA; Kucuk O; Jani AB
    Urol Oncol; 2018 Nov; 36(11):475-487. PubMed ID: 30309766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy and novel therapeutics before radical prostatectomy for high-risk clinically localized prostate cancer.
    Cha EK; Eastham JA
    Urol Oncol; 2015 May; 33(5):217-25. PubMed ID: 25596644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant and adjuvant hormonal and chemotherapy for prostate cancer.
    Lam ET; Glodé LM
    Hematol Oncol Clin North Am; 2013 Dec; 27(6):1189-204, viii. PubMed ID: 24188258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant hormone therapy for patients with high-risk prostate cancer: a systematic review and meta-analysis.
    Liu W; Yao Y; Liu X; Liu Y; Zhang GM
    Asian J Androl; 2021; 23(4):429-436. PubMed ID: 33586699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant therapy after radical prostatectomy: clinical considerations.
    Mitra A; Khoo V
    Surg Oncol; 2009 Sep; 18(3):247-54. PubMed ID: 19285386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Adjuvant and neoadjuvant drug therapy for prostate cancer].
    Miller K; Lein M; Schostak M; Schrader M
    Urologe A; 2008 Nov; 47(11):1460-4. PubMed ID: 18813902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant therapy preceding prostatectomy for prostate cancer: rationale and current trials.
    Sonpavde G; Palapattu GS
    Expert Rev Anticancer Ther; 2010 Mar; 10(3):439-50. PubMed ID: 20214524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment options for hormone-refractory prostate cancer].
    Heidenreich A; Ohlmann CH
    Urologe A; 2005 Nov; 44(11):1303-4, 1306-14. PubMed ID: 16237541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Why does androgen deprivation enhance the results of radiation therapy?
    Wo JY; Zietman AL
    Urol Oncol; 2008; 26(5):522-9. PubMed ID: 18774467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of androgen deprivation therapy prior to radical prostatectomy in high-risk prostate cancer: a systematic review.
    Arroyo-Rojas Y; Rodriguez-Sanchez L; Colandrea G; Otaola Arca H; Lanz C; Barret E; Sanchez-Salas R; Macek P; Cathelineau X
    Minerva Urol Nephrol; 2024 Apr; 76(2):141-147. PubMed ID: 38742549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.